FINWIRES · TerminalLIVE
FINWIRES

Gartner Needs to Deliver Contract Value Growth to Alleviate Concerns on Generative AI Disintermediation, RBC Says

By

-- Gartner (IT) needs to deliver substantial growth in contract value to alleviate investor concerns about the disintermediation risk of generative artificial intelligence, RBC Capital Markets said in a note emailed Wednesday.

Contract value growth in Q1 decelerated to 3.5%, not counting federal government agreements. This was due to deals postponed in March related to the conflict in the Middle East, RBC analysts said. They noted that many of these deals were actually closed in April instead.

The company ended Q1 with around $114 million in federal government contracts, and it expects a 250-basis-point drag on growth to ease in Q2 as the company laps the Department of Government Efficiency impacts, the analysts said. Gartner anticipates federal revenue for the year to be flat and return to growth in 2027, the firm noted.

The company expects contract value to accelerate growth for the rest of the year, driven by easing pressures from the government, better customer retention following major renewals, and new wins expected in Q2 and Q3 fueled by a strong pipeline, according to the note.

RBC maintained the company's stock rating at sector perform and lowered the price target to $160 from $175.

Price: $151.02, Change: $+1.53, Percent Change: +1.02%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL